The lymphatic regulator SVEP1 in Schlemm‘s canal function– a therapeutic target for glaucoma (C02)

施勒姆管（SC）通过排出眼内房水来控制眼内压（IOP）， IOP升高是青光眼的主要危险因素。目前缺乏针对SC降低IOP的药物治疗。SC类似于淋巴管，针对这种混合血管的淋巴管特征可能提供新的治疗选择。最近的全基因组关联研究表明svep1是青光眼的危险因素。我们发现SVEP1对淋巴管生成至关重要，SVEP1缺乏会导致小鼠眼压升高和青光眼。本项目旨在描述Svep1+/-增加IOP的小鼠模型，破译Svep1的作用模式，并通过重组Svep1蛋白开发青光眼的新治疗选择。

Schlemm’s canal (SC) controls intraocular pressure (IOP) by draining the aqueous humour from the eye, with increased IOP being the main risk factor for glaucoma. Medical treatments to lower IOP through targeting SC are lacking. SC resembles a lymphatic vessel, and targeting lymphatic features of this hybrid vessel might provide new treatment options. Recent Genome-wide association studies implicate SVEP 1 as risk factor for glaucoma. We found that SVEP1 is crucial for lymphangiogenesis and that Svep1 deficiency leads to increased IOP and glaucoma in mice. This project aims to describe Svep1+/- mouse models for increased IOP, decipher the mode of SVEP1 action, and to develop a new therapeutic option for glaucoma via recombinant SVEP1 protein.